by Dan Roberts
This is a summary of all major research and developments pertinent to macular degeneration that occurred between mid-May 2006 and mid-May 2007. It is organized by month of occurence under the subsets “Pharmacology,” “Surgery,” “Nutrition” and/or “Miscellaneous.” The final section, “The Future,” summarizes work in progress that may lead to promising developments in the coming year.
An audio/visual presentation of this summary is available on the International MD Support Group website. In most cases, full articles are available from the MD Support Library. Copies are permitted as long as proper credit is given.
Triple therapy found to be effective for wet AMD
Triple therapy with a combination of intravitreal Kenalog, photodynamic therapy (PDT), and intravitreal Macugen (pegaptanib sodium) has been found to be safe and effective for treatment of wet AMD. Improvements in visual acuity and in macular thickness in sixteen patients were reported at the ARVO meetings by JM Colina-Luquez MD, ophthalmologist, New England Retina Associates, Hamden, Connecticut
7.9% of those who had had prior therapy had an improvement in visual acuity of 3 lines or more, compared to 33% of those with newly diagnosed disease. This is an improvement in acuity from 20/200 to 20/50.
Macugen may present risk of increased IOP
Optometrist Allison Toler, OD (East Florida Eye Institute, Stuart, Florida) and ophthalmologist Ronald Frenkel, MD, Bascom Palmer Eye Institute, University of Miami, Miami, Florida) reported to the ARVO meeting that treatment with pegaptanib sodium (Macugen) may run the risk of significantly increased intraocular pressure (IOP). In a study of eight patients, mean pre-injection IOP was 12.9 mm Hg and mean post-injection IOP was 39.4 mm Hg. The IOP returned to normal in most cases within 30 minutes of the injection, and eventuially all patients showed normal IOP levels.
The researchers then compared Macugen injection to Avastin (bevacizumab) injection. The spikes in IOP were similar, but IOP decreased faster in patients who underwent Avastin treatment. As a result of these findings, physicians were cautioned to closely monitor IOP levels in glaucoma patients who are also being treated with Macugen.
Intravitreal injections affect the fellow eye
S.D. Martin et al (Department of Ophthalmology and Visual Sciences, University of Louisville School of Medicine, Kentucky Lions Eye Center, Louisville, KY) reported to the ARVO meeting that intravitreal injections of anti-VEGF drugs (i.e. Kenalog, Macugen and Avastin) also have an effect in the fellow eye. This is possibly the result of systemic absorption. Conclusions were drawn from analysis of pre- and post-injection ocular coherence tomography (OCT) graphs of 29 patients over a six-week period. Intravitreal use of these drugs, therefore, should be done with caution, since such absorption might also affect other systemic functions of the body. The researchers suggested that lower dosages of Macugen may be wise.
No association between cataracts and macular degeneration
Susan Bressler, MD (Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland) reported to ARVO that analyses of data from the Age Related Eye Disease Study (AREDS) has shown “no clear evidence of an association between cataract surgery and neovascular age-related macular degeneration,” and that “most patients undergoing cataract surgery can probably be reassured that surgery will not markedly increase their risk for progression to neovascular age-related macular degeneration.” The conclusion was drawn from checking outcomes after 1,704 cataract surgeries and 543 neovascular ARMD events after baseline among 8,152 eyes with a median follow-up of nine years.
New Lutein and Zeaxanthin Findings
The Melbourne Collaborative Cohort Study presented evidence to ARVO that neither lutein nor zeaxanthin are protective against the progression of AMD.
The same study of over 41,000 subjects showed an association between high intake of unsaturated fats and development of AMD, and that olive oil intake may be beneficial.
At the same meeting, a second multicenter study of 300 subjects showed that daily supplementation with 18 mg lutein and 2.4 mg zeaxanthin over six months resulted in a slight increase in macular
Blue light risk
Research from the University of Chicago has confirmed that the blue light wavelength peaking at 440 nm causes retinal damage through photochemical change and apoptotic cell death. The study authors repeated the recommendation stressed by MD Support at the 2005 ARVO meeting that blue blocking lenses be worn to protect the retina from direct exposure to strong blue light (i.e. sunlight, either natural or artificial).
Regeneron Pharmaceuticals announced positive results at the sixth week of its Phase I dose-escalation study of intravitreal anti-angiogenic drug VEGF Trap. 21 patients received a single injection of one of six doses, from 0.05mg to 4mg, and were monitored for 12 weeks.
Avastin Demonstrating Safety and Efficacy
In a paper presented at the 2006 meeting of the Association for Research in Vision and Ophthalmology researchers suggested that off-label Avastin has demonstrated safety and efficacy after over 5,000 injections. In July 2006, Lebanese researchers published positive results from a small study of 17 patients. Thirteen eyes (76%) showed total resolution of subretinal fluid, and the median acuity improved from 20/200 to 20/50. No systemic or ocular side effects were reported, but further controlled studies are needed.
Lucentis Approved for Wet AMD
On June 30, the Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection) for the treatment of patients with wet age-related macular degeneration (AMD). Lucentis is the first treatment which, when dosed monthly, can maintain the vision of more than 90 percent of patients with this type of AMD.
“This approval is of great importance for the 155,000 Americans who are diagnosed each year with AMD, a common cause of severe and irreversible vision loss in older adults,” said Dr. Andrew von Eschenbach, Acting Commissioner of Food and Drugs. “At a time when our elderly population is rapidly increasing, this product preserves quality of life for those affected by this disease, helping them to regain the ability to participate in everyday activities such as reading and driving.”
The per vial price of Lucentis is $1950. The average patient will receive between 5 and 7 treatments in the first year of therapy ($9,750 and $13,650 a year), which is covered by Medicare and secondary insurance. Most patients will have a co-pay of $50 or less per treatment. For patients who are uninsured, Genentech has established financial assistance through its Access to Care Foundation. Eligible patients who cannot afford their co-pays may be able to receive co-pay assistance through one of the independent public charities to which Genentech provides funding. For more information, call 1-866-LUCENTIS (1-866-582-3684).
Godfather gene discovered
News has come out of Sydney, Australia about a so-called “Godfather Gene” called C-jun that, if switched off, may be another way of stopping inflammation and neovascularization. Researchers based at the Centre for Vascular Research, University of NSW, have developed a drug that may be able to act as that switch.
The drug, called Dz13, targets the gene and destroys it, thus cutting off the blood supply that not only harms the retina, but also promotes cancerous tumors and inflammation. Scientists are, therefore, hoping that Dz13 will prove to be effective against several diseases, including wet macular degeneration, cancer, heart disease and arthritis.
Human trials were to begin in early 2007, so it may be several years before definite conclusions can be drawn.
New eyedrop treatment being tested for wet AMD
On August 22, 2006, Athenagen, Inc. announced that it had begun human testing of its topical (eye drop) therapy for wet AMD. Phase I trials of ATG003, a formulation of mecamylamine, are expected to generate data by the end of the year, and the company plans to move directly into a larger safety and efficacy study in early 2007.
Stem-cell procedure promising
University of Washington scientists reported on August 14, 2006 that they have successfully used stem cells to treat diseased tissue in mouse retinas.
Tom Reh, UW professor of biological structure and leader of the research, said that if such research continues to be successful, the first human tests of the technique could begin in about two years.
The UW team used a mix of “growth factors,” natural proteins that encourage cell growth to coax the embryonic cells into becoming retinal cells. When the scientists mixed the new cells with damaged mouse retina, the cells replaced key cells essential to vision. Reh said his team now have begun injecting the new cells into the eyes of retina-damaged mice to see if there is actual vision improvement. “If things,” he said, “continue to look [good] over the next six months and other research moves ahead, we should be in a position to use this for eye diseases.”
Age-related Macular Degeneration Does Not Cause Blindness
A poll sponsored by MD Support shows that a strong majority of people affected by AMD do not think of themselves as blind, and they do not want the term to be used to describe their visual impairment.
The results of a recent MD Support opinion survey show that 93% of people with AMD are averse to the use of the word “blind” in connection with their condition. 91% of them do not consider themselves to be blind, 93% know they will not go blind from AMD and 93% think the word by itself should not be used in connection with AMD. These are convincing statistics that are now available for the first time to eye care professionals, patient advocacy organizations and public service agencies. Hopefully, the message is clear and will be heeded.
Stem cell experiments slow vision loss in rats
On September 21, 2006, Raymond D. Lund, (University of Utah’s John A. Moran Eye Center in Salt Lake City) and Robert Lanza (Advanced Cell Technology Inc. in Worcester, Mass.) reported that cells grown from human embryonic stem cells slowed vision loss when injected into the eyes of rats with a disease similar to macular degeneration.
According to a recent press release (“Stem Cell Experiments Slow Vision Loss in Rats” by Rick Weiss, Washington Post, Thursday, September 21, 2006; Page A12) the researchers achieved the transformation in all 18 stem cell lines they worked with, proving that their approach can consistently produce the crucial pigment cells. Then they injected the cells, about 20,000 per eye, into the retinas of 14 rats with a genetic disease similar to macular degeneration. Eight control rats received eye injections without any cells.
Forty days after treatment, the team measured retinal electrical activity in response to flashes of light, and it found that the treated rats were twice as responsive as the untreated ones, which by then were going blind. A separate test — which tracks eye and head movements in response to a moving display, a measure of an animal’s ability to discern fine details — showed that the treated rats had twice the visual acuity of the untreated rats nearly three months after treatment.
Microscopic examination of the retinas at autopsy showed that the treated eyes had healthy photoreceptor layers five to seven cells thick, while the untreated eyes had an average thickness of just one cell. (Healthy rats have layers 10 to 12 cells thick.) None of the cells divided abnormally or grew into tumors, the team reported in the September issue of the journal Cloning and Stem Cells.
Medicare Starts Paying for Visual Rehabilitation Services
People who qualify for Medicare and whose eyesight has significantly declined due to macular degeneration, diabetes or certain other conditions can now get up to nine hours of vision rehabilitation through a new Medicare-sponsored demonstration project.
The five-year project is available in six areas of the United States: Atlanta, New York City, New Hampshire, Kansas, North Carolina and the state of Washington. It will allow the Centers for Medicare and Medicaid Services (CMS) to study the demand for – and effectiveness of – services aimed at helping visually impaired individuals make the most of their remaining vision.
After the project concludes, administrators will decide whether to extend reimbursement for those services to all Medicare recipients across the country, Greene said. “We think there’s a strong possibility that they’ll do that.”
In the six areas chosen, Medicare will pay for therapy services provided in clinics or at home by certified vision rehabilitation therapists, orientation and mobility specialists, low vision therapists and occupational therapists, but not the low vision aids themselves.
New Molecule Discovered
Case Western Reserve University and the Cleveland Clinic Cole Eye Institute have discovered a molecule that triggers neovascularization in the retina. Called Carboxyethylpyrroles (CEPs), it attaches to proteins in the retina, causing blood vessel growth that leads to sight loss in wet AMD. The next step is to identify the receptors that are activated by the CEPs and then develop drugs that can block the formation of the toxic molecule.
Leaders in the Low Vision Industry Reach Consensus on Important Patient Issues
MD Support took part in a roundtable discussion hosted by the National Association of Visually Handicapped in Washington, D.C. It proved to be informative and worthwhile, as the participants left with a better understanding of the concerns of patients and a consensus of opinions on potential improvements in care and management. Leaders from twelve advocacy, health and research organizations were present, in addition to representatives from Novartis Ophthalmics (sponsors) and the National Eye Institute. Three main topics were discussed in the day-long session:
1. Identifying and appreciating patient expectations and experiences with AMD diagnosis and treatment in order to help health care personnel provide individualized, efficient and holistic treatment.
2. The role of support services in helping AMD patients continue to perform daily tasks and maintain a positive attitude.
3. The language used to discuss the effects of AMD on vision and the effects of using terms such as “visually impaired,” “legally blind” and “blind.”
Unanimous consensus was reached on three principal issues:
1. Patients must be guided to information and emotional support immediately upon diagnosis. This would be best accomplished through support services at the clinic, direction to low vision counseling and/or guidance to reliable community and Internet resources.
2. Areas of concern that need to be addressed by support services are activities in daily living (including transportation), low vision evaluation, counseling, orientation and mobility, employment, and library resources.
3. To help lessen the often profound emotional response to a diagnosis of AMD, sensitivity is needed in the language used to describe the condition. In particular, the word “blind” should not be used without qualification to describe AMD to patients.
A Safer Way to Treat SAD(ness)
Research has shown that melatonin is a necessary antioxidant for physical and psychological health. The high point of the melatonin cycle, however, lasts 9-10 hours, and the average person does not have (or allow) that much time to sleep. Blue light exposure during the day may make a person less drowsy and depressed by suppressing melatonin levels in the blood, but the body still needs up to 10 hours of high melatonin levels for peak health.
Compounding the dilemma, blue light exposure appears to lead to macular degeneration in some people, due to interruption of the photoreceptor cells’ metabolic visual cycle (see www. mdsupport. org/library/hazard.html). This makes blue light therapy risky, especially for people with compromised retinas.
The obvious answer is to get more sleep; but for those who cannot do so, one option to potentially harmful blue light therapy has been proposed by Richard L. Hansler, Ph.D. (Director, Lighting Innovations Institute, John Carroll University. Executive Director, Light and Health Foundation). Dr. Hansler’s well-thought-out suggestion is to allow full completion of the melatonin cycle by avoiding blue light for 9-10 hours, beginning before sleep and continuing until morning. One easy way to accomplish this would be to simply wear your blue-blocking glasses for awhile before going to bed. Another is to switch to lamps that filter blue wavelengths.
New Anti-angiogenic Drugs Enter Trials
Two new drugs are now in trials to test their safety and efficacy in treatment of wet AMD. On October 31, MacuSight, Inc. announced the start of a Phase I study of sirolimus (rapamycin). On November 1, 2006, TargeGen announce the initiation of Phase I trials involving the prodrug, TG100801.
Sirolimus, which is injected into the eye, differs from other anti-angiogenic drugs in that it is a highly-potent, broad-acting compound that may be useful in treating a wide range of ocular diseases and conditions. TG100801 is administered as an eye drop, which makes it attractive to patients who are now having to undergo injections that are uncomfortable and carry certain risks.
New Gene Discovery Provides Potential Marker for AMD
The protein Complement Factor H (CFH) has previously been found to play a role in the development of drusen leading to AMD. CFH has implicated inflammation as part of the AMD pathogenesis, and now, discovery of a new gene may complete the picture. Researchers have recently found that a single mutation in the gene HTRA1 on chromosome 10q26 is a major genetic risk factor for wet AMD.
Studies that genotyped 581 people with AMD and 309 without AMD have provided a strong predictor for individuals who have family histories of the disease. A blood test to identify the mutant HTRA1 gene can now identify those who are up to seven times more likely to develop AMD than those with a normal gene. Not only will this allow such individuals to take preventative steps to lower their risk, but identification of the gene as a drug target can bring about new treatments for AMD and other retinal diseases brought on by drusen formation.
Drusen Lasering Ineffective
Drusen are thought to be fatty waste products from the photoreceptor cells. They often appear on the macula (the center of the retina) in the early stages of macular degeneration, and they can cause gradual loss of central vision.
In 1999, ophthalmologists took an interest in using the laser to destroy drusen, based upon the theory that ridding the retina of these deposits may slow the development of MD, or even stop the progression from the “dry” form to the “wet” form. Two studies, however, have recently shown drusen lasering to be ineffective, and even potentially harmful, as a treatment for macular degeneration. The studies were called Complications of AMD Prevention Trial (CAPT) and Prophylactic Treatment of AMD (PTAMD).
In 2006, PTAMD researchers reported that laser treatment “to an eye with multiple large drusen in a patient whose fellow eye has already suffered a neovascular event places the treated eye at higher risk of developing choroidal neovascularization.” They concluded by advising against using prophylactic subthreshold diode laser treatment in these eyes.
Then, on November 1, 2006, the National Eye Institute announced that their CAPT studies have been small, and the results inconsistent. No difference in vision or in progression to advanced AMD between treated and untreated eyes were observed, so doctors are advised to reconsider drusen lasering as a treatment for AMD.
Exercise May Protect Against Wet AMD
A study at the University of Wisconsin has shown that regular exercise may help to prevent the wet form of age-related macular degeneration (AMD). As reported in the November 2006 issue of British Journal of Ophthalmology, the study monitored almost 4,000 people between the ages of 43 and 86 over a period of 15 years. Researchers discovered that those who engaged in regular physical activity at least three times a week were 70% less likely to develop neovascularization. One explanation put forth is that– like coronary disease–inflammation, high cholesterol and high blood pressure are suspected to contribute to the development of wet AMD, and exercise helps to reduce those three conditions. The study showed that exercise had no effect on the incidence of dry AMD.
Avastin still showing success
Three abstract sessions at the AAO meeting in December revealed that intravitreal treatment with bevacisumab (Avastin) for wet AMD and pathologic myopia is showing no systemic adverse events and that the off-label drug is showing success in inhibiting neovascularization and improving visual acuity. The general conclusion is that re-treatment is needed at 2-3 month intervals. The study titles were:
“Safety and effectiveness of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia” (Hernandez-Rojas, ML, et al, abstract #673).
“Intravitreal bevacizumab (Avastin) in the treatment of neovascular age-related macular degeneration” (Avery, RL, et al, abstract #673).
“Intravitreal bevacizumab (Avastin) for recurrent choroidal neovascularization” (Frederico Graue-Wiechers, et al, abstract #722).
Updates on anti-angiogenic drug studies
At the same meeting, reports were presented on recent research in the areas of antiangiogenic drug therapy for wet AMD, including Genentech’s MARINA and PIER studies of ranibizimab (Lucentis) and Alcon’s progress on the anecortave acetate (Retaane 15 mg) trials. Nothing particularly new was presented, but some interesting findings were discussed:
Elias Reichel, M.D. reported that in the MARINA trials, there was improvement at all visual acuity levels, but there was not a big difference if the patient’s baseline vision was either low or excellent. This “floor-to-ceiling” effect is not unusual with this kind of study, but it is useful information for patient communicating with patients about expectations.
Nancy Holekamp, M.D., discussed key anatomic endpoints in the MARINA trials, in particular, the total lesion area over time (no growth of the lesion area was noted in the treated patients), the mean area of leakage (the amount of decrease was statistically significant) and the mean foveal retinal thickness (treated eyes showed a significant thinning of the retina). The bottom line is that all anatomic outcomes from the trial favored Lucentis, and the treatment is so effective over a long period of time without any signs of toxicity, there is no indication that anything in lieu of Lucentis should be used to treat wet AMD.
Peter Kaiser, M.D., reported on subgroup analysis of Genentech’s PIER study. The primary endpoint was met, showing a difference of 16 letters visual acuity between the treated group and the sham group. Further, the dosing regimen was effective, but the visual acuity benefit was not as robust when injections went from monthly to quarterly. The persistence of monthly injections may depend upon who has dry lesions and who has wet lesions at the 5th month. The dry lesion group did better than the wet lesion group with quarterly dosing. This data is pointing toward better prediction of dosage outcomes for individual patients.
Jason Slakter, M.D., reported that Alcon’s anecortave acetate has shown weak anti-angiogenic activity, but the method of treatment (injection outside of the eyeball) gives it the chance to have an effect over a longer period of time. This, he said, justifies continuing the study in the face of the impressive Lucentis results.
Melissa Brown, M.D., M.N., M.B.A. (Center for Value-Based Medicine) addressed the question, “On what basis can doctors compare pharmacologic treatments for wet AMD?” She suggested value-based analysis, looking at both quality of life and cost, and starting with an examination of the evidence. In a comparison of several current interventions, she noted that Lucentis shows the highest percentage in quality of life, but highest in cost. Still, Lucentis–at approximately $50,000 per quality of life year–is within commonly accepted parameters in the field of medicine.
John Thompson, M.D., reported no significant difference in three dose levels of Acuity Pharmaceutical’s bevasiranib, an anti-VEGF small interfering RNA drug with the ability to turn off genes that cause wet AMD. Results indicate that treatment with direct VEGF inhibitors may be necessary initially before treatment with bevasirinab. Hopefully, a Phase III study will show effectiveness as long term treatment.
RHEO Therapy Back in Trials
It was recently announced here that OccuLogix’s multicenter MIRA-1 study failed to prove effectiveness of its RHEO System, a blood filtration device being used in Canada for treating dry AMD. Now the company has announced that it has obtained clearance from the FDA to commence a new phase III study called RHEO-AMD. If successful, the results are expected to support OccuLogix’s application to the FDA for approval to market its RHEO System in the United States.
Another source of stem cells
On January 7, 2007, researchers at the Institute for Regenerative Medicine at Wake Forest University School of Medicine discovered another potential source of embryonic stem cells in the amniotic fluid that protects babies in the womb. These cells appear to be almost as malleable as those in the embryo itself, and the advantage would be that harvesting them would not harm the embryo. Several more years of study are needed to assess their application in humans.
Lucentis Approved in Europe
Novartis AG announced on January 24, 2007 that Lucentis (ranibizumab) has received European Union approval for patients with wet age-related macular degeneration. According to a press release issued by the company, the EU commission decision applies to all 27 member states as well as Iceland and Norway. Lucentis will be launched in Europe beginning this year. It has already won approval in the United States, Switzerland and India.
Lucentis and Risk of Stroke
The media has recently reported on a letter sent by Genentech to retina specialists highlighting rates of stroke observed in their Phase IIIb SAILOR study of Lucentis.
Genentech has found in their planned 6-month interim analysis that 1.2 percent of patients treated with a high dose of Lucentis in a clinical trial suffered a stroke, compared with only 0.3 percent of those treated with a low dose. The difference was statistically significant.
MD Support encourages patients to not overreact to this news. The letter was simply a proactive attempt on behalf of Genentech to provide additional information to treating physicians. The observed rates of stroke in the SAILOR trials are within those observed in the MARINA and ANCHOR pivotal studies that lead to the FDA approval of Lucentis and that were reported in October in the New England Journal of Medicine. The FDA still stands with its approval based upon the trial results, which are clearly reported in the Lucentis package insert. (None of the Genentech studies, by the way, excluded patients with cardiovascular conditions.)
Avastin Benefits Patients With CNV From Myopic Degeneration
On February 15, 2007, Elias Reichel, M.D. reported to Hawaiian Eye/Retina 2007 that Avastin has shown good results in a small retrospective case series for treatment of choroidal neovascularization (CNV) from myopic degeneration. 15 eyes studied showed a mean improvement in acuity of 3 lines, central foveal thickness decreased an average of 93 µm (micrometers) and there were no complications.
CA4P for Myopic Degeneration Successfully Completes Phase II
Oxigene, Inc. has reported positive results from its safety and efficacy phase trials of CA4P in the treatment of myopic macular degeneration. Safety results were favorable and in line with expectations, with no drug related serious adverse events being reported.
The company also announced that it has completed a pre-IND meeting with the FDA regarding two topical ophthalmic formulations (eye drops and ocular mini-tabs) for CA4P in the treatment of age-related macular degeneration and intends to proceed with further development of topical formulations.
New anti-angiogenic eyedrops
On February 26, 2007, Othera Pharmaceuticals presented new preclinical data demonstrating the safety and effectiveness of OT-551, an antiangiogenic drug in eyedrop form. Results from the Phase I trials demonstrated that when the compound is added to either Lucentis or Avastin treatment there is a synergistic effect versus either treatment alone. Phase II trials are expected to begin in the second quarter of this year.
Another company, Athenagen, Inc., has announced successful completion of Phase I of a trial testing its topical (eye drop) drug ATG3 for wet AMD. On January 31, 2007, the company announced successful completion of Phase I, and that “the eye drop therapy showed excellent ocular tolerability. There were no study medication-related systemic side effects, consistent with the very low levels of the compound found in the blood following eye drop application.” Athenagen’s Phase II clinical trial is expected to begin in the first quarter of 2007.
Lucentis shown to be better than PDT
On February 15, 2007, Peter Kaiser, M.D. reported two-year results of the Phase 3 ANCHOR trial comparing Lucentis with photodynamic therapy (PDT) for wet AMD. The study showed that Lucentis helps maintain vision, with few adverse effects, significantly better than PDT. For details, see www.lucentis.com.
Positive Results From Combined Radiation/Avastin Treatment for Wet AMD
NeoVista, Inc. reports positive results from NVI-111 Study (concomitant radiation/Anti-VEGF) for the treatment of wet AMD. Using the Epi-Rad 90(TM) Ophthalmic System, manufactured by NeoVista, treatment involved intravitreal 24 Gy Strontium-90 beta radiation plus initial treatment with Avastin. At six months, 45% of the patients treated per protocol achieved >=3 lines of visual acuity gain. This compares favorably to the results obtained in Genentech’s MARINA Trial, which utilized 0.5 mg of Lucentis alone. In addition, all patients treated in this study achieved a mean change in visual acuity of 13.4 letters at 6 months, which compares favorably to the reported 6.5 letter gain at month six of the MARINA Trial.
NeoVista will soon begin its CABERNET trial incorporating the concomitant use of Lucentis and Epi-Rad 90 therapy. For more information, visit the company website at www.neovistainc.com.
DHA supplement trial
Retina South Africa E-News announced a Phase ll trial in the U.S. to test the effect of the fish oil supplement Docosahexaenoic Acid (DHA) on X-linked retinitis pigmentosa (RP). Some researchers believe that DHA supplementation may also slow the progress of the dominant form of RP and age related macular degeneration. Other research, however, has shown that oxidized forms of DHA are found in drusen. No patients should self-medicate without first consulting an eye care practitioner.
Zinc May Harm the Retina: New Finding
BBC News announced on March 18 that researchers at London’s Institute of Ophthalmology think the mineral zinc may play a role in the development of AMD. The study, published in Experimental Eye Research, found that drusen containing high levels of zinc may contribute to progression of the disease. When asked for her opinion on this new development, nutritionist Ellen Troyer, CEO of BioSyntrx, Inc., said:
“I’m carefully watching these studies. There is another study published in the Journal of Urology that links the ARED study participants to a much higher incidence of kidney problems. We [at BioSyntrx] repeatedly have said in every talk we give (as has every biochemist I know) that 80 mg of zinc is way too much for daily consumption, and that has been our position since the ARED study was published. This does not mean, however, that we should not supplement with reasonable amounts of zinc, because it is vital to good health. And it is beyond appalling that they continue to use zinc oxide when there are much safer forms of zinc.”
We will continue to stay in touch with Ms Troyer for updates. Meanwhile, anyone taking the AREDS formula containing high amounts of zinc may want to consider switching to a multi-supplement with less.
Visually Impaired, Not Blind
The word “blind” is becoming increasingly less associated with age-related macular degeneration (AMD). MD Support reports that the majority of press releases and media broadcasts are now using the more correct terms “low vision,” “vision loss” or “visual impairment.”
Dan Roberts, director of MD Support, spent five months tracking virtually every public article and news broadcast about macular degeneration appearing on the Internet. As of November 10, 2006, he had found that 58% were still using the word “blind” as a description of AMD. As of March 10, 2007, he reports that the ratio had dropped to 42%, and the trend is continuing downward.
Beta-carotene May be Ineffective in Fighting Macular Degeneration
Vitamin A in the form of beta-carotene has been found to be ineffective in slowing the progression of maculopathies such as age-related macular degeneration (AMD). This conclusion was derived from a follow-up study derived from the Physicians’ Health Study 1, which found neither benefit nor harm from 12 years of supplementation with beta carotene on cancer or cardiovascular disease. The follow-up study found that beta-carotene also had no significant effect on development of AMD, advanced maculopathy or maculopathy with or without vision loss.
The landmark age-related eye disease study (AREDS) found that a high-dosage formula of antioxidants and zinc, which included beta-carotene, was effective in slowing the progression of AMD. Beta-carotene, however, was not studied separately. The supplement might still be indirectly effective when taken in combination with other antioxidants, but that has yet to be researched.
As always, MD Support recommends that patients consult with both their general physicians and eye care specialists before making any significant changes in dietary supplements.
Lucentis and Avastin comparable as first-line treatments
N.J. Sund, M.M. et al reported to the ARVO meeting that further evidence of the safety and efficacy of intravitreal Avastin and Lucentis as first line monotherapy in the treatment of neovascular AMD. In their study, both drugs showed comparable results as first line treatments in terms of visual acuity outcomes in the short term. (abstract title: Efficacy of Intravitreal Bevacizumab (AvastinTM) vs. Ranibizumab (LucentisTM) as First Line Monotherapy for the Treatment of Neovascular Age-Related Macular Degeneration?)
Cataract surgery and AMD
R.C. Milton, et al reported to the ARVO meeting that their large clinic-based longitudinal cohort study showed no clear evidence of an association between cataract surgery and the geographic atrophy form of advanced AMD. Patients undergoing cataract surgery can probably be reassured that the surgery is unlikely to increase their risk.
(Abstract title: The Effect of Cataract Surgery on the Development of Geographic Atrophy)
Blue light and macular degeneration
A.R. Wielgus, et al reported to the ARVO meeting that blue light exposure promotes the oxidation of A2E and iso-A2E in rodent eyes. A2E is a blue light absorbing retinal chromophore that increases with age. The researchers noted that, as A2E oxides are toxic to retinal tissue, this may partially explain blue light induced retinal injury. This study is another in a growing compendium of research pointing to a connection between blue light and macular degeneration. (abstract title: Blue Light Induces A2E Oxidation in Rat’s Eyes)
Ultraviolet radiation and macular degeneration
A.J. Harring, et al reported to the ARVO meeting that subjects who were exposed to higher levels of ultraviolet (UV) radiation for the majority of their lifetimes were less likely to develop neovascular (wet) AMD than subjects who were exposed to lower UV levels. These results should not be confused with studies that have shown a connection between UV exposure and the increased risk of corneal disease and retinal cell damage.
(Abstract title: UVR Exposure and Risk of Neovascular Age-Related Macular Degeneration)
T.I. Metelitsina, et al reported to the ARVO meeting that inreased blood circulation may result in the resolution of drusen. This conclusion was drawn from observing eyes that show more drusen reduction following laser treatment and noting that those eyes have larger increases in choroidal circulatory parameters. The 23 subjects were drawn from the Complication of Age-Related Macular Degeneration Prevention trial (CAPT). (Abstract title: Laser Induced Resolution of Drusen Is Associated With Increases in Choroidal Blood Flow)
Effects of cardiovascular disease and hypertension on AMD
U.Chakravarthy, et al reported to the ARVO meeting that cardiovascular disease is strongly implicated as an etiological factor in the development of choroidal neovascularisation in a proportion of older adults. The researchers emphasize the importance of control of blood pressure and cholesterol, avoidance of smoking and maintenance of a normal body weight. This is further evidence linking cardiovascular disease and high blood pressure with wet macular degeneration.
(Abstract title: Cardiovascular Disease and Hypertension Are Strong Risk Factors for Choroidal Neovascularisation)
Dietary antioxidants ineffective in preventing AMD
E.W. Chong, et al reported to the ARVO meeting that there is insufficient evidence from the published literature to support the role of dietary antioxidants, including the use of dietary antioxidant supplements, for the primary prevention of early AMD. This conclusion was based upon a systematic review and meta-analysis of 9 prospective cohort studies and 3 randomized clinical trials of dietary antioxidants and dietary antioxidant supplements.
Pooled results from prospective cohort studies suggested that vitamin A, vitamin C, zinc, lutein, zeaxanthin, beta-carotene, cryptoxanthin and lycopene have little or no effect in the primary prevention of early AMD, and Vitamin E had a modest protective association for early AMD. The three randomized clinical trials did not show antioxidant supplements to be protective in the primary prevention of early AMD.
This study shows that antioxidants and zinc will not prevent the onset of AMD. It does not dispute the original ARED study, which showed that antioxidants and zinc can moderately lower the risk of developing the wet form of the disease in patients with advanced AMD.
(Abstract title: Dietary Antioxidants and Primary Prevention of Age-Related Macular Degeneration:A Systematic Review and Meta-Analysis)
NSAIDs and progression to advanced AMD
H.Sen, et al reported to the ARVO meeting that there was no significant association between regular systemic use of anti-inflammatory drugs (aspirin or NSAIDs) and the likelihood of developing advanced AMD (defined as the development of either neovascular AMD or central geographic atrophy). This conclusion was drawn from data collected over a median of 11 years from the original AREDS group.
(Abstract title: Systemic NSAIDs and Age-Related Macular Degeneration: The Age-Related Eye Disease Study (AREDS)
Statins may not prevent CNV
C.A. McCannel1, et al reported to the ARVO meeting that there is no consensus in the literature on whether or not statins offer protection against progression to the advanced stage of AMD (defined as the development of either choroidal neovascularization (CNV) or central geographic atrophy (CGA) in patients with early AMD. Data gathered from subjects in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT) do not support the concept of a strong protective effect of statins against the development of CNV. CAPT statin users did have a lower risk of GA, but not to a statistically significant degree.
(Abstract title: Statin Use and the Incidence of Choroidal Neovascularization and Geographic Atrophy in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT)
Phototrop continues to show effectiveness
J.Feher, et al reported to the ARVO meeting that “prospective case studies on the long term effects of Phototrop treatment (see www.mdsupport.org/library/phototrop.html) confirmed the previous clinical trial’s data on an initial improvement followed by stabilization of visual functions in early AMD. Surprisingly, fundus alterations may further improve after one year of treatment, as shown by three different objective methods. All of these findings give further support to the efficacy of the long term use of Phototrop in early AMD patients, as early AMD may continue to improve even after 12 months of use.”
(Abstract title: Long Term Improvement of Early AMD Treated With Phototrop: Prospective Case Studies)
Statins, smoking and wet AMD
A scientific abstract presentation at the 2005 AAO meeting, “Reduced Risk of Progression to Exudative ARMD with Statin Use” (Gregory R Nettune, MPH, et al) presented research finding that “the risk of exudative AMD was increased by smoking and reduced by use of statins. Further, the duration of statin use up to four years was associated with an increasing degree of protection.” The study also found that current smoking or smoking within the past 20 years led to a 6-fold increase in risk of conversion from dry to wet AMD. No difference was found in subjects who had not smoked in 20 years.
As reported at the 2006 ARVO meeting, research from Duke and Vanderbilt University Medical Centers (published in the online edition of the American Journal of Human Genetics, March 6, 2006) has discovered that a version of the LOC387715 gene significantly increases the risk of developing ARMD in tobacco smokers. This is an unusual instance wherein genetics and environment can combine to create a disease risk. The other example related to ARMD is the CFH gene and how its effects are related to the body’s immune system.
A more recent study (Johanna M Seddon, et al, “Association of CFH Y402H and LOC387715 A69S With Progression of Age-Related Macular Degeneration,” JAMA, April 2007) showed that common variants of CFH and LOC387115 increased the risk of progression to advanced AMD. The variants, called Single Nucleotide Polymorphisms (SNP), independently increased the risk of progression from early or intermediate stages to advanced stages of AMD by 2.6 times (CHF) and 4.1 times (LOC387715). The presence of both risk genotypes, when combined with smoking and body mass index of 25+, increased the AMD progression risk 19-fold.
Low vision devices and reading speed
N.Nguyen, et al reported to the ARVO meeting that their study confirms the importance and efficiency of visual rehabilitation with low vision aids. The researchers evaluated magnification requirement and reading ability before and after administration of appropriate low-vision aids to 484 patients with different stages of AMD.
Mean reading speed [words per minute] was 20±33 before and 72±35 after administration of low vision aids. With appropriate low-vision aid, patients increased their reading speed an average of 53±19 wpm. Patients with a lower magnification requirement (less than 10X) showed a higher increase of reading speed (59±31 wpm) than patients with high magnification requirement (40±18 wpm).
The researchers concluded that “all patients benefited greatly from the rehabilitation measures in optimizing reading ability and therefore qualify of life. In face of the increasing number of elderly patients with AMD, rehabilitation should start as early as possible.”
(Abstract title: Reading Ability Before and After Administration of Low-Vision Aids in Patients With Age-Related Macular Degeneration)
Encapsulated cell technology
Phase 2 of the encapsulated cell technology (ECT) trial to deliver growth factors to the retina is ongoing. Phase 1 trials (see www.mdsupport.org/library/summary2006.html) showed an unexpected improvement in vision. This 2 year trial is being funded by the National Eye Institute in hopes that slow delivery of the growth factors will preserve photoreceptor function and serve as a drug delivery system for other conditions, as well. For more information, see www.mdsupport.org/library/ect.html.
A second age-related eye disease study (AREDS 2) is looking at changes to the original formula. Potential changes include lowering the amount of zinc, eliminating beta-carotene, and including the carotenoids lutein, zeaxanthin, and DHA/Omega 3 (fish oil). The study, which will collect data from about 4000 subjects over the next five years, is being sponsored by the National Eye Institute.
AREDS2 is now recruiting participants with bilateral large drusen or advanced in one eye. All participants will be followed annually with a minimum follow-up of 5 years. For more information, see http://www.areds2.org.
Implantable miniature telescope
VisionCare’s Phase clinical trials of the IMT have been successfully completed, and a 2-year follow-up has revealed no serious safety issues. The company now looks forward to completing the regulatory review process on the way to marketing the IMT for public use by the end of this year.
New Drug In Trials for Dry AMD
Fenretinide (ST-602), a drug that has been used to treat certain cancers, rheumatoid arthritis, acne, and psoriasis, has been found to also slow the production and accumulation of a toxin that leads to vision loss in macular degeneration patients. The toxin, called A2E, is a byproduct of vitamin A, the formation of which encourages production of waste deposits called lipofuscin. These deposits accumulate in the retinal pigment epithelium (RPE), interfering with the RPE’s ability to nourish the photoreceptors.
Early research showed that A2E accumulation was decreased by 60% in mouse models after 28 days of treatment with fenretinide. Sirion Therapeutics, Inc. is now running FDA-approved multi-center studies using up to 225 AMD patients as subjects. If the drug proves effective with dry AMD patients, it may then be used off-label for treatment of Stargardt’s disease, a juvenile form of MD.